Showing 1 - 10 of 77
Uncertainty in the decision-making process for reimbursement of health technologies could be reduced if additional information were available. Although methods to evaluate the monetary value of the uncertainty have been previously described, an economic evaluation of alternative methods to...
Persistent link: https://www.econbiz.de/10005590472
DOI: 10.2165/0019053-200826100-00009
Persistent link: https://www.econbiz.de/10004997788
Persistent link: https://www.econbiz.de/10001767485
HPV poses a significant burden in terms of health (clinical and quality of life) and in monetary terms, even for conditions that are sometimes regarded as benign, such as CIN1 or genital warts. Current findings should be used for proper evaluation of measures to reduce HPV-related morbidity and...
Persistent link: https://www.econbiz.de/10011000866
Background:Background: Human papillomavirus (HPV) infection is mostly associated with cervical cancer (CC). However, it can cause other illnesses as well, all of which impact on people's wellbeing and consume healthcare resources. Measures for prevention or early detection of these conditions...
Persistent link: https://www.econbiz.de/10009647783
Innovative health technologies are often the focus of attention. However, in the allocation of public resources for improving health, the focus should be on the health needs of the population. It is the need that should be analyzed first, and decision makers should then evaluate the full range...
Persistent link: https://www.econbiz.de/10005077615
Persistent link: https://www.econbiz.de/10011869108
Persistent link: https://www.econbiz.de/10001215607
Persistent link: https://www.econbiz.de/10011299677
Persistent link: https://www.econbiz.de/10003771226